FADD phosphorylation is critical for cell cycle regulation in breast cancer cells

British Journal of Cancer

Volumn 94, Issue 4, 2006, Pages 532-539

  Matsuyoshi, S ^a   Shimada, K ^a   Nakamura, M ^a   Ishida, E ^a   Konishi, N ^a  

^a NARA MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Breast cancer; c jun N terminal kinase; Cell cycle arrest; Fas associated death domain; Immunohistochemistry; Phosphorylation

Indexed keywords

ESTROGEN RECEPTOR; FAS ASSOCIATED DEATH DOMAIN PROTEIN; PACLITAXEL; SERINE; STRESS ACTIVATED PROTEIN KINASE; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER THERAPY; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE REGULATION; CELL GROWTH; CELL LINE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DNA FLANKING REGION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INHIBITION KINETICS; MAJOR CLINICAL STUDY; METASTASIS; MITOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CELL CYCLE; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; PHOSPHORYLATION; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 33344457562     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602955     Document Type: Article

References (29)

1. Alappat EC, Feig C, Boyerinas B, Volkland J, Samuels M, Murmann AE, Thorburn A, Kidd VJ, Slaughter CA, Osborn SL, Winoto A, Tang WJ, Peter ME (2005) Phosphorylation of FADD at serine 194 by CKIalpha regulates its nonapoptotic activities. Mol Cell 19: 321-332
2. Alappat EC, Volkland J, Peter ME (2003) Cell cycle effects by C-FADD depend on its C-terminal phosphorylation site. J Biol Chem 278: 41585-41588
3. Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM (1995) FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 81: 505-512
4. Cianfrocca M, Goldstein LJ (2004) Prognostic and predictive factors in early-stage breast cancer. Oncologist 9: 606-616
5. Colpaert C, Vermeulen P, Jeuris W, van Beest P, Goovaerts G, Weyler J, Van Dam P, Dirix L, Van Marck E (2001) Early distant relapse in 'node-negative' breast cancer patients is not predicted by occult axillary lymph node metastases, but by the features of the primary tumour. J Pathol 193: 442-449
6. Fumoleau P, Bonneterre J, Luporsi E (2003) Adjuvant chemotherapy for node-positive breast cancer patients: which is the reference today? J Clin Oncol 21: 1190-1191: author reply 1191-1192
7. Gagandeep S, Novikoff PM, Ott M, Gupta S (1999) Paclitaxel shows cytotoxic activity in human hepatocellular carcinoma cell lines. Cancer Lett 136: 109-118
8. Geard CR, Jones JM, Schiff PB (1993) Taxol and radiation. J Natl Cancer Inst Monogr 15: 89-94
9. Guerra I, Algorta J, Diaz de Otazu R, Pelayo A, Farina J (2003) Immunohistochemical prognostic index for breast cancer in young women. Mol Pathol 56: 323-327
10. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei E, Schilsky RL, Wood WC, Muss HB, Norton L (2003) Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21: 976-983
11. Imai Y, Kimura T, Murakami A, Yajima N, Sakamaki K, Yonehara S (1999) The CED-4-homologous protein FLASH is involved in Fas-mediated activation of caspase-8 during apoptosis. Nature 398: 777-785
12. Izeradjene K, Douglas L, Delaney AB, Houghton JA (2004) Casein kinase I attenuates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by regulating the recruitment of fas-associated death domain and procaspase-8 to the death-inducing signaling complex. Cancer Res 64: 8036-8044
13. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE, Nicholson RI (2003) Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144: 1032-1044
14. Kuhling H, Alm P, Olsson H, Ferno M, Baldetorp B, Parwaresch R, Rudolph P (2003) Expression of cyclins E, A, and B, and prognosis in lymph node-negative breast cancer. J Pathol 199: 424-431
15. Liao CH, Pan SL, Guh JH, Teng CM (2004) Genistein inversely affects tubulin-binding agent-induced apoptosis in human breast cancer cells. Biochem Pharmacol 67: 2031-2038
16. Madsen MW, Reiter BE, Larsen SS, Briand P, Lykkesfeldt AE (1997) Estrogen receptor messenger RNA splice variants are not involved in antiestrogen resistance in sublines of MCF-7 human breast cancer cells. Cancer Res 57: 585-589
17. Mingo-Sion AM, Marietta PM, Koller E, Wolf DM, Van Den Berg CL (2004) Inhibition of JNK reduces G2/M transit independent of p53, leading to endoreduplication, decreased proliferation, and apoptosis in breast cancer cells. Oncogene 23: 596-604
18. Moriguchi T, Toyoshima F, Masuyama N, Hanafusa H, Gotoh Y, Nishida E (1997) A novel SAPK/JNK kinase, MKK7, stimulated by TNFalpha and cellular stresses. EMBO J 16: 7045-7053
19. Nagata S, Golstein P (1995) The Fas death factor. Science 267: 1449-1456
20. Paulsen GH, Strickert T, Marthinsen AB, Lundgren S (1996) Changes in radiation sensitivity and steroid receptor content induced by hormonal agents and ionizing radiation in breast cancer cells in vitro. Acta Oncol 35: 1011-1019
21. Regitnig P, Schippinger W, Lindbauer M, Samonigg H, Lax SF (2004) Change of HER-2/neu status in a subset of distant metastases from breast carcinomas. J Pathol 203: 918-926
22. Scaffidi C, Volkland J, Blomberg I, Hoffmann I, Krammer PH, Peter ME (2000) Phosphorylation of FADD/MORT1 at serine 194 and association with a 70-kDa cell cycle-regulated protein kinase. J Immunol 164: 1236-1242
23. Shimada K, Matsuyoshi S, Nakamura M, Ishida E, Kishi M, Konishi N (2004) Phosphorylation of FADD is critical for sensitivity to anticancer drug-induced apoptosis. Carcinogenesis 25: 1089-1097
24. Shimada K, Matsuyoshi S, Nakamura M, Ishida E, Konishi N (2005) Phosphorylation status of Fas-associated death domain-containing protein (FADD) is associated with prostate cancer progression. J Pathol 206: 423-432
25. 2-terminal kinase-mediated pathways in 2-methoxyestradiol-induced p53 induction and apoptosis. Carcinogenesis 24: 1067-1075
26. Shimada K, Nakamura M, Ishida E, Kishi M, Yonehara S, Konishi N (2002) Phosphorylation of Fas-associated death domain contributes to enhancement of etoposide-induced apoptosis in prostate cancer cells. Jpn J Cancer Res 93: 1164-1174
27. Suo Z, Risberg B, Kalsson MG, Willman K, Tierens A, Skovlund E, Nesland JM (2002) EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. J Pathol 196: 17-25
28. Tishler RB, Geard CR, Hall EJ, Schiff PB (1992) Taxol sensitizes human astrocytoma cells to radiation. Cancer Res 52: 3495-3497
29. Zhang Y, Qiu WJ, Chan SC, Han J, He X, Lin SC (2002) Casein kinase I and casein kinase II differentially regulate axin function in Wnt and JNK pathways. J Biol Chem 277: 17706-17712